Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02636322 | Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT02926833 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)(ZUMA-6) | completed | Phase 1 / Phase 2 | 37 | Kite, A Gilead CompanyINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT00019097 | Vaccine Therapy in Treating Patients With Multiple Myeloma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00235560 | Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients(LAM-RAPA) | completed | Phase 2 | 50 | University Hospital, ToulouseOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT02034981 | Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1(AcSé) | completed | Phase 2 | 246 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02012088 | Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb | completed | Phase 2 | 91 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT02441803 | Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT03335267 | Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia | completed | Phase 2 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT02056756 | Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Stichting European Myeloma NetworkNETWORK | 2 | Feb 20, 2024 | clinicaltrials |
| NCT00577278 | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | completed | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT01812252 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant(ICT-HCT) | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04478123 | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | completed | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02435849 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ELIANA) | completed | Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 13, 2024 | clinicaltrials |
| NCT02473146 | Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4(ALFA1401) | completed | Phase 2 / Phase 3 | 225 | Versailles HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03155425 | PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma | completed | Phase 2 | 75 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT01522469 | Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations | completed | Phase 2 | 14 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02653976 | A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | completed | Phase 2 | 67 | Solasia Pharma K.K.INDUSTRY | 4 | Jan 26, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01190787 | Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone | completed | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02663622 | Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) | completed | Phase 2 | 44 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT02385110 | Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT01858922 | Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A(TXCH-HD-12A) | completed | Phase 2 | 40 | Baylor College of MedicineOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT01991457 | Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia(FluTBI) | completed | Phase 2 | 19 | University of Alabama at BirminghamOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03506360 | Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05045443 | Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia(CurcumPedALL) | completed | Phase 2 | 30 | Ain Shams UniversityOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT03399513 | Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma(R-CHOEP-brut) | completed | Phase 2 | 40 | University Hospital MuensterOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04956666 | A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)(ALL) | completed | Phase 2 | 75 | Institut de Recherches Internationales ServierOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT02789254 | FLYSYN in MRD Positive AML(FLYSYN-101) | completed | Phase 1 / Phase 2 | 31 | Synimmune GmbHINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT00004192 | Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | University of NebraskaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT00004198 | Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma | completed | Phase 2 | — | University of NebraskaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT00007865 | Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | — | University of NebraskaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT00031642 | Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 26 | University of NebraskaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT00520767 | Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease | completed | Phase 2 | 35 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT02626338 | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | completed | Phase 1 / Phase 2 | 16 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03483103 | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | completed | Phase 2 | 74 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05028374 | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | completed | Phase 2 | 119 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT02400255 | Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients | completed | Phase 2 | 30 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04682405 | Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) | completed | Phase 2 | 51 | Washington University School of MedicineOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT01913730 | Maintenance Therapy With Subcutaneous Bortezomib | completed | Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02561273 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 54 | University of NebraskaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03734601 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT01393756 | Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma(R2-CHOP2) | completed | Phase 2 | 80 | The Lymphoma Academic Research OrganisationOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02509546 | 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02843074 | Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | completed | Phase 2 | 53 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03436862 | Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT01145209 | Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 13, 2024source: clinicaltrials